Make commercial-scale GMP CAP-1002 product available
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 May 2023
- Due
- 30 Sep 2023
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“plan to have commercial-scale GMP CAP-1002 product available in the third quarter of 2023.”
What we found
Evidence strength A What the grades mean
The company's San Diego facility was identified as a pilot facility in 2024, and FDA comparability for commercial use was not established until March 2024, indicating commercial-scale product was not available in 2023.
-
A Capricor Therapeutics, Inc. 10-Q filed 2024-05-14
“At that meeting [March 2024] the FDA agreed that comparability between drug product manufactured at our two different facilities (Los Angeles and San Diego) has been demonstrated... This will now allow for the use of CAP-1002 drug product manufactured at our San Diego manufacturing facility upon pot” ✓ confirmed on the page
Market reaction: the shares moved +2.2% against the S&P 500 over the three sessions around the disclosure (13 May 2024 to 16 May 2024). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Facility other
- Indicative materiality
- Medium rules
- Action
- Make
- Deliverable
- Commercial-scale GMP CAP-1002 product
- Where
- San Diego
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: disagreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and read it as “no_evidence”, so a person decides.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Capricor Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-CAPR-002526 · Corrections policy